Shares of Pliant Therapeutics, Inc. (PLRX) plummeted by 5.99% on Wednesday, despite the biopharmaceutical company reporting better-than-expected earnings for the third quarter of 2024.
According to the company's earnings report, Pliant Therapeutics reported an adjusted loss of $0.95 per share for the quarter ended September 30, 2024, beating analysts' consensus estimate of a $0.97 loss per share. However, the company recorded zero revenue for the quarter, falling short of analysts' expectations of around $0.5 million.
Despite the narrower-than-expected loss, Pliant Therapeutics reported a substantial quarterly net loss of $57.76 million, which may have weighed on investor sentiment. Additionally, while the stock had gained 35.5% during the third quarter, it was still down 16.1% year-to-date, raising concerns about the company's overall performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.